CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) – Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today provided an update on progress in the MANIFEST Phase 2 clinical trial of CPI-0610 in myelofibrosis (MF). The Company also reviewed its 2018 accomplishments and announced its data […]
04: First Hematologist Appointment for Polycythemia Vera Patient
MPN Chronicles Podcast – 04, PV Reporter, Always Ask Your Doctor for your CBC or your test results and keep a binder to Monitor your Progress by David Wallace After 2 visits to the ER, I finally had my first hematologist meeting. She reviewed the tests that were done in the ER and ran a […]
PV Reporter partners with PAN Foundation on MPN Patient Assistance Programs
Patient Assistance Programs, Medications for MPN Patients by David Wallace PV Reporter is very proud to announce a new partnership with the PAN Foundation. Myeloproliferative Neoplasm (MPN) patients may be eligible for $8,500 per year (or more if a 2nd grant is needed/approved) in assistance assuming you meet the eligibility criteria which are very reasonable. […]
Dr. Jean Jacques Kiladjian ASH 2018 RuxoPeg Phase 1/2 Trial of the Combo of Ruxolitinib and Pegasys in Myelofibrosis Patients
RUXOPEG is the first study to formally assess the safety and efficacy of Rux + IFNa combination in MF patients never exposed to either drugs before First in ASH 2018 Series by David Wallace Dr Jean Jacques Kiladjian, Professor of Clinical Hematology, Hopital Saint-Louis, Paris, France interviews with David Wallace, PV Reporter at ASH 2018. […]
